Viridian Therapeutics (VRDN) Competitors $17.41 -0.11 (-0.63%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$17.42 +0.00 (+0.03%) As of 08/1/2025 04:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VRDN vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, WGS, and ADUSShould you be buying Viridian Therapeutics stock or one of its competitors? The main competitors of Viridian Therapeutics include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), GeneDx (WGS), and Addus HomeCare (ADUS). These companies are all part of the "healthcare" industry. Viridian Therapeutics vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group GeneDx Addus HomeCare Viridian Therapeutics (NASDAQ:VRDN) and Guardant Health (NASDAQ:GH) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Do insiders & institutionals hold more shares of VRDN or GH? 92.6% of Guardant Health shares are owned by institutional investors. 1.6% of Viridian Therapeutics shares are owned by company insiders. Comparatively, 6.1% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Which has more volatility & risk, VRDN or GH? Viridian Therapeutics has a beta of 0.42, suggesting that its stock price is 58% less volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.43, suggesting that its stock price is 43% more volatile than the S&P 500. Do analysts recommend VRDN or GH? Viridian Therapeutics currently has a consensus target price of $37.00, suggesting a potential upside of 112.52%. Guardant Health has a consensus target price of $54.95, suggesting a potential upside of 32.66%. Given Viridian Therapeutics' higher probable upside, research analysts plainly believe Viridian Therapeutics is more favorable than Guardant Health.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viridian Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 0 Strong Buy rating(s) 2.89Guardant Health 0 Sell rating(s) 0 Hold rating(s) 19 Buy rating(s) 1 Strong Buy rating(s) 3.05 Does the media prefer VRDN or GH? In the previous week, Guardant Health had 18 more articles in the media than Viridian Therapeutics. MarketBeat recorded 26 mentions for Guardant Health and 8 mentions for Viridian Therapeutics. Guardant Health's average media sentiment score of 0.96 beat Viridian Therapeutics' score of 0.65 indicating that Guardant Health is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Viridian Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Guardant Health 11 Very Positive mention(s) 2 Positive mention(s) 9 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has better valuation & earnings, VRDN or GH? Viridian Therapeutics has higher earnings, but lower revenue than Guardant Health. Guardant Health is trading at a lower price-to-earnings ratio than Viridian Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViridian Therapeutics$300K4,734.94-$269.95M-$3.85-4.52Guardant Health$739.02M6.99-$436.37M-$3.35-12.36 Is VRDN or GH more profitable? Guardant Health has a net margin of -49.93% compared to Viridian Therapeutics' net margin of -102,092.39%. Guardant Health's return on equity of 0.00% beat Viridian Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viridian Therapeutics-102,092.39% -70.61% -44.67% Guardant Health -49.93%N/A -28.95% SummaryGuardant Health beats Viridian Therapeutics on 13 of the 17 factors compared between the two stocks. Get Viridian Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VRDN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VRDN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VRDN vs. The Competition Export to ExcelMetricViridian TherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.43B$2.99B$5.48B$9.54BDividend YieldN/A2.43%4.73%4.09%P/E Ratio-4.5217.7428.8623.83Price / Sales4,734.94178.75371.7266.14Price / CashN/A41.9535.4557.96Price / Book2.868.508.275.54Net Income-$269.95M-$55.06M$3.25B$259.28M7 Day Performance0.75%-3.99%-3.73%-4.68%1 Month Performance14.31%9.58%4.29%4.36%1 Year Performance14.77%6.70%25.87%17.89% Viridian Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VRDNViridian Therapeutics1.1779 of 5 stars$17.41-0.6%$37.00+112.5%+6.9%$1.43B$300K-4.5250News CoverageShort Interest ↑GHGuardant Health4.5812 of 5 stars$44.27-0.3%$54.45+23.0%+24.2%$5.50B$774.00M-13.062,021Trending NewsEarnings ReportAnalyst ForecastOPCHOption Care Health4.6336 of 5 stars$29.77+0.3%$35.50+19.2%-8.2%$4.86B$5.00B24.018,088News CoveragePositive NewsEarnings ReportAnalyst ForecastAnalyst RevisionRDNTRadNet4.0802 of 5 stars$57.83+0.7%$69.60+20.4%-5.7%$4.31B$1.83B-134.4911,021Positive NewsBTSGBrightSpring Health Services2.9288 of 5 stars$20.48-0.2%$24.90+21.6%+60.6%$3.61B$11.27B33.1135,000Trending NewsEarnings ReportGap DownSHCSotera Health2.444 of 5 stars$12.29-0.1%$16.00+30.2%-18.2%$3.49B$1.10B19.843,000Upcoming EarningsSGRYSurgery Partners2.9422 of 5 stars$22.44+5.6%$33.33+48.5%-29.6%$2.72B$3.11B-14.6715,000Positive NewsUpcoming EarningsGap UpCONConcentra Group Holdings Parent2.9017 of 5 stars$20.05+2.0%$28.50+42.1%-14.0%$2.52B$1.90B14.5611,250Positive NewsUpcoming EarningsPRVAPrivia Health Group3.9004 of 5 stars$19.70-0.1%$28.38+44.1%-8.0%$2.40B$1.74B164.181,140Upcoming EarningsWGSGeneDx3.0164 of 5 stars$84.91+6.4%$92.33+8.7%+215.0%$2.28B$305.45M87.721,200News CoverageEarnings ReportAnalyst ForecastInsider TradeOptions VolumeGap DownHigh Trading VolumeADUSAddus HomeCare4.9425 of 5 stars$109.11-0.3%$142.57+30.7%-13.9%$2.01B$1.15B24.6349,703Positive NewsUpcoming Earnings Related Companies and Tools Related Companies GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors WGS Competitors ADUS Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VRDN) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersWhy Elon put $51 million into thisA single U.S. company has started producing a “miracle metal” once locked in research labs. Now? They’re qu...True Market Insiders | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Stre...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viridian Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viridian Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
